GlassScriptPhysician profile
Lorena Alianza-Timog
NPI 1528496742
$2,780.08
in general payments reported to CMS, 2019-2025
24 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $642 · 2023: $446 · 2024: $669 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $560.31 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $411.69 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Medtronic, INC. | $387.61 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $330.47 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $130.65 | 2021 | |
| Pharmacosmos Therapeutics INC. | $120.29 | 2024 | Monoferric |
| Novartis Pharmaceuticals Corporation | $112.12 | 2025 | |
| Cequr Corporation | $103.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.02 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.57 | 2022-2024 | |
| Dexcom, INC. | $90.38 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $81.86 | 2023-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $49.23 | 2021-2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $38.38 | 2021-2023 | Gvoke Hypopen |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.25 | 2024 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $20.41 | 2025 | Twiist |
| Kyowa Kirin, INC. | $18.36 | 2025 | |
| Axsome Therapeutics, INC. | $18.14 | 2025 | Sunosi |
| Embecta Corp. | $17.00 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Rhythm Pharmaceuticals, INC. | $16.79 | 2024 | Imcivree |
| Amgen INC. | $16.00 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.45 | 2024 | Farxiga |
| Mannkind Corporation | $14.93 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Alianza-Timog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.